KEVIN HUANG: Open Payments
NPI 1831378975 · PHILA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,825 in 75 payments from 10 companies in 2025. Trend: 2023 $2,031 · 2024 $2,385 · 2025 $3,825
Food & beverage: $3,714Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $813 |
| Janssen Pharmaceuticals, Inc | 14 | $726 |
| Otsuka America Pharmaceutical, Inc. | 7 | $568 |
| E.R. Squibb & Sons, L.L.C. | 9 | $476 |
| Janssen Scientific Affairs, LLC | 3 | $360 |
| ABBVIE INC. | 9 | $262 |
| Neurocrine BioSciences, Inc. | 5 | $210 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $195 |
| Alkermes, Inc. | 4 | $154 |
| Lundbeck LLC | 3 | $60 |
Products named: INVEGA SUSTENNA, UZEDY, COBENFY, REXULTI, ABILIFY MAINTENA, VRAYLAR, INGREZZA, CAPLYTA.
Industry payments across PA — which companies pay providers there.
